PL1803456T3 - Kompozycje farmaceutyczne zawierające L-733060 do zastosowania w leczeniu guzów nowotworowych - Google Patents

Kompozycje farmaceutyczne zawierające L-733060 do zastosowania w leczeniu guzów nowotworowych

Info

Publication number
PL1803456T3
PL1803456T3 PL05708080T PL05708080T PL1803456T3 PL 1803456 T3 PL1803456 T3 PL 1803456T3 PL 05708080 T PL05708080 T PL 05708080T PL 05708080 T PL05708080 T PL 05708080T PL 1803456 T3 PL1803456 T3 PL 1803456T3
Authority
PL
Poland
Prior art keywords
treatment
pharmaceutical compositions
cancer tumours
tumours
cancer
Prior art date
Application number
PL05708080T
Other languages
English (en)
Inventor
Sáez Miguel Munoz
Original Assignee
Nk 1 Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nk 1 Ip Ltd filed Critical Nk 1 Ip Ltd
Publication of PL1803456T3 publication Critical patent/PL1803456T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL05708080T 2004-02-11 2005-02-10 Kompozycje farmaceutyczne zawierające L-733060 do zastosowania w leczeniu guzów nowotworowych PL1803456T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200400424A ES2246687B2 (es) 2004-02-11 2004-02-11 Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
EP05708080.6A EP1803456B1 (en) 2004-02-11 2005-02-10 Pharmaceutical compositions comprising L-733060 for use in the treatment of cancer tumours
PCT/ES2005/000068 WO2005077366A1 (es) 2004-02-11 2005-02-10 Utilización de antagonistas no peptídicos de receptores nk1 para la producción de apoptosis en células tumorales

Publications (1)

Publication Number Publication Date
PL1803456T3 true PL1803456T3 (pl) 2015-08-31

Family

ID=34854896

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05708080T PL1803456T3 (pl) 2004-02-11 2005-02-10 Kompozycje farmaceutyczne zawierające L-733060 do zastosowania w leczeniu guzów nowotworowych

Country Status (12)

Country Link
US (4) US9867814B2 (pl)
EP (2) EP1803456B1 (pl)
AU (1) AU2005211955B2 (pl)
CA (1) CA2566315C (pl)
CY (1) CY1116415T1 (pl)
DK (1) DK1803456T5 (pl)
ES (2) ES2246687B2 (pl)
HK (1) HK1208192A1 (pl)
PL (1) PL1803456T3 (pl)
PT (1) PT1803456E (pl)
SI (1) SI1803456T1 (pl)
WO (1) WO2005077366A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246687B2 (es) 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
WO2009124756A1 (en) * 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Use of aprepitant and derivatives thereof for the treatment of cancer
ES2376564B1 (es) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
US20150297613A1 (en) 2011-12-13 2015-10-22 Servicio Andaluz De Salud Use of agents that alter the peritumoral environment for the treatment of cancer
ES2493693B1 (es) 2013-02-11 2015-07-07 Servicio Andaluz De Salud Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
ES2541870B1 (es) 2013-12-27 2016-05-12 Servicio Andaluz De Salud Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
US20160324881A1 (en) * 2013-12-30 2016-11-10 Oncoprevent Gmbh Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
CA2947509A1 (en) * 2014-04-29 2015-11-05 Servicio Andaluz De Salud Method for diagnosing and monitoring the presence of cancer in a human subject
CA2956022A1 (en) * 2014-07-24 2016-01-28 Plus Vitech,S.L Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract
ES2595442B1 (es) * 2015-05-27 2017-10-04 Consejo Superior De Investigaciones Cientificas (Csic) Antagonistas de los receptores nk1 derivados de hidratos de carbono, metodo de obtencion y uso medico
US20260102417A1 (en) * 2022-09-29 2026-04-16 Keyzell Holding S.L. Compositions for the treatment and prevention of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
EP0584256B1 (en) * 1991-04-22 1999-11-10 Mallinckrodt Medical, Inc. Compounds and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
CA2189501A1 (en) * 1995-11-06 1997-05-07 Harry R. Howard Nk-1 receptor antagonists for the treatment of cancer
US6037340A (en) * 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
IT1306165B1 (it) * 1999-07-05 2001-05-30 Innova Ltd Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
US20010034320A1 (en) * 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
HUP0300413A2 (hu) 2000-04-10 2003-06-28 Pfizer Products Inc. Amidcsoportot viselő benzolgyűrűs csoporttal helyettesített piperidint tartalmazó és rokonszerkezetű vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1385577B1 (en) * 2001-04-23 2006-04-19 F. Hoffman-la Roche AG Use of nk-1 receptor antagonists against benign prostatic hyperplasia
US6713490B2 (en) * 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US20050227929A1 (en) * 2003-11-13 2005-10-13 Masferrer Jaime L Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
JP2008536881A (ja) 2005-04-21 2008-09-11 ガストロテック・ファルマ・アクティーゼルスカブ Ｇｌｐ−１分子と制吐剤との医薬製剤
WO2009124756A1 (en) * 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Use of aprepitant and derivatives thereof for the treatment of cancer

Also Published As

Publication number Publication date
AU2005211955A1 (en) 2005-08-25
EP1803456B1 (en) 2014-11-26
US20180117027A1 (en) 2018-05-03
CY1116415T1 (el) 2017-02-08
SI1803456T1 (sl) 2015-05-29
US9867814B2 (en) 2018-01-16
ES2246687B2 (es) 2006-11-16
EP2842605A3 (en) 2015-03-18
EP2842605A2 (en) 2015-03-04
EP1803456A1 (en) 2007-07-04
WO2005077366B1 (es) 2005-09-15
HK1208192A1 (en) 2016-02-26
CA2566315C (en) 2013-08-27
DK1803456T5 (da) 2015-06-22
US20090012086A1 (en) 2009-01-08
US20150224095A1 (en) 2015-08-13
WO2005077366A1 (es) 2005-08-25
US20200054620A1 (en) 2020-02-20
ES2246687A1 (es) 2006-02-16
PT1803456E (pt) 2015-03-04
AU2005211955B2 (en) 2011-06-23
ES2535184T3 (es) 2015-05-06
CA2566315A1 (en) 2005-08-25
DK1803456T3 (en) 2015-03-02
HK1105886A1 (en) 2008-02-29

Similar Documents

Publication Publication Date Title
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
PT2601961T (pt) Composições compreendendo lag-3 e anticorpos terapêuticos e as suas utilizações no tratamento de cancro
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
GB2453011B (en) Antifolate agent compositions in the treatment of cancer
IL218317A (en) Use of 15-il polypeptide preparations and 15-il complexes for the preparation of cancer drugs
EP2038041A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
IL191938A (en) The ovarian heterocellular compounds, pharmaceuticals containing them, and the ovarian heterocellular compounds for cancer treatment
PL1765391T3 (pl) Kompozycje bakteryjne do leczenia nowotworów
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL213897A0 (en) Ultrasound contrast agent dosage formulation
GB0523576D0 (en) Drug composition and its use in therapy
PT1803456E (pt) Composições farmacêuticas que compreendem l-733060 para utilização no tratamento de tumores cancerígenos
IL183893A0 (en) Pharmaceutical compositions for the treatment of cellulite
ZA200709542B (en) Combination therapy in the treatment of cancer
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
PT2340872T (pt) Novas formulações farmacêuticas úteis no tratamento de insónia
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
GB2443588B (en) A pharmaceutical composition useful for the treatment of prostate cancer
ZA200701578B (en) Combination anticancer therapy and pharmaceutical compositions therefore